Recommended composition of influenza virus vaccines for use in the 2025-2026 northern hemisphere influenza season

Overview

The WHO recommends that trivalent vaccines for use in the 2025-2026 northern hemisphere influenza season contain the following: 

Egg-based vaccines

• an A/Victoria/4897/2022 (H1N1)pdm09-like virus;

• an A/Croatia/10136RV/2023 (H3N2)-like virus; and

• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

Cell culture-, recombinant protein- or nucleic acid-based vaccines

• an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;

• an A/District of Columbia/27/2023 (H3N2)-like virus; and

• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus. 

The recommendation for the B/Yamagata lineage component of quadrivalent influenza vaccines remains unchanged from previous recommendations:

• a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.